Infex strengthens its senior leadership team
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's broader pipeline and growth strategy.
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s new five-year national action plan to help combat…
Infex to present webinar on broader pipeline and growth strategy
Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a webinar for investors, analysts, and media on 9th…
Webinar on Infex’s Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead Phase II asset, RESP-X.
Infex to present webinar on lead Phase II respiratory drug RESP-X
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
No adverse events reported across all cohorts
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
RESP-X continues to exhibit strong safety and tolerability profile
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate